Regadenoson
DrugAdministered as an intravenous (IV) bolus
Other names: Lexiscan, CVT3146
NCT Number: NCT01618669
The purpose of this study is to demonstrate that the strength of agreement between single photon emission computed tomography (SPECT) imaging with regadenoson following inadequate exercise stress testing and SPECT imaging with regadenoson alone is not inferior to the strength of agreement between two sequential regadenoson SPECT images without exercise.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
Hospital Italiano Garibaldi, Rosario, Santa Fe Province, Argentina
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Administered as an intravenous (IV) bolus
Other names: Lexiscan, CVT3146
Time frame: Day 1 (rest scan and first stress scan) and Day 2 -15 (second stress scan)
SPECT scans were reviewed in a blinded fashion by 3 independent expert readers using the 17-segment model for standardized myocardial segmentation. At rest and stress, each segment was scored on a 0 (normal) to 4 (absent contrast/radiotracer uptake) scale by each of the 3 blinded readers according to the amount of contrast or radiotracer the myocardium in the segment absorbed. If the stress score was ≥ 2 and the rest score was less than the stress score, the segment was counted as having a reversible defect.
The number of segments with reversible defects was categorized as absence (0 - 1 reversible segments) or presence (≥ 2 defects reversible segments) of ischemia.
Each reader was defined as having self-agreement based upon identical categorization of a given participant as absent or present for ischemia for both the initial and second stress visits.
Majority agreement is if at least 2 out of the 3 blinded readers demonstrated self-agreement for a given participant.
Time frame: Within 1 hour for ECG events and up to 24 hours for adverse events after administration of regadenoson
A clinically significant cardiac event is defined as:
Or
Or
Time frame: Day 1 (stress MPI 1) and Day 2 -15 (stress MPI 2)
The number of segments with reversible defects was assessed by each of the 3 blinded independent expert readers. Based on the median count of the number of reversible defects across the 3 readers, categorized as absence (0 to 1 reversible segments) or presence (≥ 2 reversible defects) of ischemia, the proportion of participants with agreement in the presence and absence of ischemia between the first and second stress scans was calculated.
Time frame: Day 1 (stress MPI 1) and Day 2 - 15 (stress MPI 2)
The number of segments with reversible defects was assessed by each of the 3 blinded independent expert readers. Based on the median count of the number of reversible defects across the 3 readers, categorized as 0 to 1, 2 to 4, or ≥ 5 reversible segments, the proportion of participants with agreement in the three ischemia categories between the first and second stress scans was to be calculated. In the reported data, these proportions only include the 0-1 and 2-4 categories; the ≥ 5 category was not included because there were no participants in this category for the Regadenoson Alone group for the initial stress MPI.
Time frame: Day 1 (stress MPI 1) and Day 2 - 15 (stress MPI 2)
The 17-segment model for standardized myocardial segmentation was used to analyze MPI scans. Each segment was scored on a 0 to 4 scale according to the amount of contrast or radiotracer the myocardium in the segment absorbed:
The Summed Stress Score (SSS) was calculated as the sum of the stress scores across the 17 segments. The mean value (rounded to the nearest integer) across the 3 readers was computed and the SSS was categorized into 4 group categorical variables based on the score: 0 to 3, 4 to 7, 8 to 11, and ≥ 12. The proportion of participants with agreement in respect to these categories between the two stress scans was calculated.
Time frame: Day 1 (rest MPI and stress MPI 1) and Day 2 - 15 (stress MPI 2)
The 17-segment model for standardized myocardial segmentation was used to analyze MPI scans. At rest and stress, each segment was scored on a 0 to 4 scale according to the amount of contrast or radiotracer the myocardium in the segment absorbed:
SSS was calculated as the sum of the stress scores across the 17 segments and the Summed Rest Score (SRS) was calculated as the sum of the rest scores across the 17 segments. The Summed Difference Score (SDS) is the difference in the SSS and SRS (SSS - SRS).
The mean value (rounded to the nearest integer) across the 3 readers was computed and the SDS was categorized into 3 categorical variables based on the score: 0 to 6, 7 to 13 and ≥ 14. The proportion of participants with agreement in respect to these categories between the two stress scans was calculated.
Time frame: Day 1 (stress MPI 1) and Day 2-15 (stress MPI 2)
Each reader evaluated the initial stress SPECT MPI scan compared to the participant's second stress SPECT MPI scan (blinded at time of the evaluation) for whether there was Less (-1), the Same (0) or More (1) reversible perfusion defects. The median assessment of the 3 blinded readers was used to summarize the number of participants in each category.
Time frame: Day 1 (rest MPI and stress MPI 1) and Day 2 - 15 (stress MPI 2)
The image quality for each scan was rated by each independent reader as 1 = Poor, 2 = Fair, 3 = Good, 4 = Excellent. Based on the median rating of overall image quality across the three readers, the number of participants with each rating is reported for each scan.
Time frame: Day 1 (stress MPI 1) and Day 2 - 15 (stress MPI 2)
Image quality was assessed through radiotracer uptake in the heart (target organ) compared to liver, gut and combined liver plus gut (background interference).
Time frame: Day 1 (stress MPI 1) and Day 2 -15 (stress MPI 2)
Each reader assessed the sub-diaphragmatic radiotracer interference with cardiac image quality using a 4-point scale of 0 = none, 1 = slight, 2 = moderate or 3 = severe for each stress SPECT MPI. The median rating across the 3 readers was used to summarize the percentage of scans with interference.
Time frame: Day 1 (stress MPI 1) and Day - 15 (stress MPI 2)
The number of cardiac segments obscured by the sub-diaphragmatic activity by group by stress SPECT MPI scan and by reader is reported.
Time frame: Up to 24 hours after study drug administration for each stress MPI (Day 1 and Day 2-15)
An adverse event is considered "serious" if, in the view of either the investigator or sponsor, it results in any of the following outcomes:
Relationship to study drug was assessed by the investigator.
Astellas Pharma Global Development, Inc.
Industry
A Phase 3b, Open-Label, Parallel Group, Randomized, Multicenter Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)
Acronym: EXERRT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00265525
Arterial Occlusive Diseases, Arteriosclerosis
London, Ontario, Canada
View Trial DetailsNCT07473596
Arterial Occlusive Diseases, Arteriosclerosis
Helsinki, Uusimaa, Finland
View Trial DetailsNCT05292092
Arterial Occlusive Diseases, Arteriosclerosis
Algeciras, Spain
View Trial DetailsNCT04936867
Arterial Occlusive Diseases, Arteriosclerosis
Frankfurt am Main, Hesse, Germany
View Trial Details